# Australian Shepherd Health Problems: MDR1 Gene and Ivermectin Drug Sensitivity


## Key Takeaways

- The MDR1 gene mutation, a deletion of four base pairs, results in a non-functional P-glycoprotein pump, critically impairing the blood-brain barrier's ability to exclude certain drugs.
- Australian Shepherds with the MDR1/MDR1 genotype (affected) are at high risk of severe, life-threatening neurological toxicity from standard doses of ivermectin, loperamide, and certain chemotherapy agents due to drug accumulation in the central nervous system.
- A simple cheek swab DNA test is the definitive diagnostic method to determine a dog's MDR1 genetic status (Normal N/N, Carrier MDR1/MDR1, or Affected MDR1/MDR1), enabling veterinarians to select safe drug alternatives.
- Clinical signs of ivermectin toxicity in affected dogs can range from mild ataxia and hypersalivation to severe seizures, coma, and death, often appearing within hours to days of drug administration.
- Prevention is paramount; owners must know their dog's MDR1 status and inform all veterinarians, avoiding ivermectin, loperamide, and other P-glycoprotein substrates, opting instead for alternatives like isoxazolines for parasite prevention.

---

If you own an Australian Shepherd, the single most important genetic health issue to understand is the MDR1 gene mutation, also known as the multidrug resistance mutation. This mutation directly causes severe, potentially fatal drug sensitivity to ivermectin and several other common medications. The definitive answer for any Australian Shepherd owner is this: you must know your [dog](/knowledge/veterinary-medicine/clinical-methods/dog)'s MDR1 genetic status before your veterinarian prescribes any medication, particularly parasite preventives containing ivermectin, loperamide (Imodium), or certain chemotherapy agents. A simple cheek swab DNA test provides a definitive answer, and this knowledge allows your veterinarian to select safe, effective alternatives, ensuring your dog lives a long, healthy life without accidental poisoning.

## At a Glance: MDR1 Status and Drug Safety

This table provides a rapid reference for owners and veterinary professionals. It summarizes the clinical relevance of each genetic status.

| Genetic Status | Genotype | Clinical Significance for Ivermectin | Safe Parasite Prevention Options (Examples) | Action Required |
| :--- | :--- | :--- | :--- | :--- |
| **Normal** | N/N (two normal copies) | Standard doses of ivermectin are generally safe. High doses (for mange treatment) still require veterinary supervision. | Most standard heartworm preventives (e.g., ivermectin/pyrantel), milbemycin oxime, selamectin. | None specific to MDR1. |
| **Carrier** | MDR1/MDR1 (one mutant, one normal copy) | Increased risk of neurological toxicity compared to normal dogs, but often less severe than affected dogs. Some drugs are still contraindicated. | Isoxazolines (e.g., afoxolaner, sarolaner), milbemycin oxime, selamectin (with caution). | Avoid high-dose ivermectin. Use caution with loperamide. Discuss all new medications with your vet. |
| **Affected** | MDR1/MDR1 (two mutant copies) | **High risk of severe, life-threatening neurological toxicity** even at standard preventive doses. Ivermectin is strictly contraindicated. | Isoxazolines (e.g., afoxolaner, sarolaner) are generally safe. Milbemycin oxime is often used but with caution. | Strictly avoid ivermectin, loperamide, and certain other drugs. Always inform any new veterinarian of this status. |

## Understanding the MDR1 Gene and Its Function

The MDR1 gene provides the instructions for creating a protein called P-glycoprotein. This protein acts as a crucial biological pump, primarily located in the cells lining the digestive tract, the cells of the blood-brain barrier, and in the liver and kidneys. Its primary function is to pump potentially harmful substances, including many drugs and toxins, *out* of cells and back into the intestines or bile for elimination from the body.

In the brain, P-glycoprotein is a key component of the blood-brain barrier. It actively pumps drugs out of the brain tissue and back into the bloodstream, protecting the central nervous system from their effects. In Australian Shepherds and other herding breeds, a specific mutation in the MDR1 gene (a deletion of four base pairs) results in a non-functional or truncated P-glycoprotein. This means that affected dogs cannot effectively pump certain drugs out of their brain. When a dog with this mutation is given a drug like ivermectin, the drug accumulates to toxic levels in the central nervous system, leading to neurological signs that can range from mild disorientation to coma and death.

## Why Australian Shepherds Are Affected

The MDR1 mutation is an inherited, autosomal recessive trait. This means a dog must inherit two copies of the mutant gene, one from each parent, to be "affected" and show the most severe drug sensitivities. Dogs with only one copy of the mutation are called "carriers" and may show intermediate sensitivity to some drugs.

This mutation is highly prevalent in Australian Shepherds and is a primary reason why this breed is frequently discussed in the context of breed-specific health problems. While the mutation is also found in Collies, Shetland Sheepdogs, and other herding breeds, its high frequency in the Australian Shepherd population makes genetic testing a critical component of responsible breed ownership. The decision to breed only genetically normal (N/N) dogs is a key strategy to eliminate this health problem from future generations.

## The Core Problem: Ivermectin Drug Sensitivity

Ivermectin is a broad-spectrum antiparasitic agent widely used in veterinary medicine. It is the active ingredient in many common heartworm preventives and is also used at higher doses to treat conditions like mange (demodicosis) and certain [intestinal parasites](/knowledge/parasites/pet-parasites/intestinal-parasites-dogs-cats-identification-treatment).

In a dog with a normal MDR1 gene, the P-glycoprotein in the blood-brain barrier protects the central nervous system from ivermectin's effects. However, in an Australian Shepherd with the MDR1 mutation, this protective mechanism is absent or deficient. When ivermectin enters the brain, it interferes with neurotransmission, leading to a cascade of neurological symptoms.

### Clinical Signs of Ivermectin Toxicity

The signs of ivermectin toxicity in an MDR1-affected dog can appear within a few hours to a couple of days after drug administration. The severity depends on the dose of the drug and the dog's specific genetic status. Signs can include:

- **Early signs:** Lethargy, depression, excessive drooling, vomiting, lack of coordination (ataxia), and dilated pupils.
- **Progressive signs:** Tremors, disorientation, blindness, and difficulty breathing.
- **Severe signs:** Coma, seizures, respiratory failure, and death.

**Emergency Red Flags:** If your Australian Shepherd shows any of these signs after receiving any medication, especially a parasite preventive, seek immediate emergency veterinary care. This is a life-threatening situation.

## Other Drugs to Avoid with the MDR1 Mutation

The MDR1 mutation affects more than just ivermectin. Several other common drugs are substrates for P-glycoprotein and can cause severe adverse reactions in affected dogs. It is vital to share your dog's MDR1 status with your veterinarian before any new medication is prescribed.

Key drugs to avoid or use with extreme caution in MDR1-affected dogs include:

- **Loperamide (Imodium):** An over-the-counter anti-diarrheal medication. It can cause severe sedation and neurological signs in affected dogs.
- **Chemotherapeutic Agents:** Drugs like doxorubicin and vincristine are P-glycoprotein substrates. Affected dogs may experience more severe bone marrow suppression and other toxicities.
- **Other Macrocyclic Lactones:** This class includes drugs like selamectin, milbemycin oxime, and moxidectin. While often safer than ivermectin, they can still cause toxicity in affected dogs, especially at higher doses.
- **Certain Antiemetics:** Drugs like maropitant (Cerenia) are also affected by the MDR1 mutation, potentially leading to increased sedation.

## Veterinary Examination and Diagnostics

If you suspect your Australian Shepherd has been exposed to a toxic drug, your veterinarian will perform a thorough physical and neurological examination. They will also take a complete history, including any medications or preventives your dog has received.

### Definitive Genetic Testing

The only way to know your dog's MDR1 status with certainty is through genetic testing. This is a simple and non-invasive test that can be performed at any age, even in puppies.

- **How it's done:** A veterinarian collects a sample using a sterile cheek swab (buccal swab) or a small blood sample. The sample is sent to a specialized veterinary genetics laboratory.
- **What it tests for:** The test specifically looks for the presence of the mutant MDR1 gene. Results are reported as:
    - **Normal (N/N):** The dog has two normal copies of the gene and is not affected.
    - **Carrier (M/M):** The dog has one normal and one mutant copy. It is a carrier and can pass the mutation on to its offspring.
    - **Affected (M/M):** The dog has two mutant copies and is highly sensitive to the drugs mentioned above.

### Diagnosing Toxicity

If a dog is showing signs of toxicity, there is no specific test for ivermectin levels in most clinical settings. The diagnosis is typically based on:

1.  **History:** A recent history of drug administration.
2.  **Clinical Signs:** The presence of neurological signs consistent with the drug's effects.
3.  **Known MDR1 Status:** If the dog has a known MDR1 mutation, this heavily supports the diagnosis.

## Evidence-Based Management and Treatment of Toxicity

Treatment for ivermectin or other drug toxicity in an MDR1-affected dog is primarily supportive and symptomatic. There is no antidote to reverse the drug's effects directly. The goal is to stabilize the patient and give the body time to metabolize and eliminate the drug.

### Immediate and Intensive Care

- **Induction of Vomiting:** If the drug was ingested very recently (within 1-2 hours), the veterinarian may induce vomiting to remove unabsorbed medication. This is only safe if the dog is not already showing severe neurological signs.
- **Activated Charcoal:** This can be administered to bind any remaining drug in the gastrointestinal tract and prevent further absorption.
- **Intravenous Fluids:** IV fluids are crucial to maintain hydration, support blood pressure, and help the kidneys excrete the drug.
- **Seizure Control:** If the dog is having seizures, anti-seizure medications like diazepam or barbiturates are used.
- **Respiratory Support:** In severe cases, the dog may require oxygen therapy or mechanical ventilation if breathing is compromised.
- **Nursing Care:** Affected dogs often require intensive nursing, including turning them regularly to prevent bedsores, maintaining body temperature, and providing nutritional support.

### Prognosis

The prognosis for a dog with MDR1-related drug toxicity is guarded and depends on the dose of the drug and how quickly treatment is initiated. Dogs that receive prompt, aggressive supportive care have a better chance of recovery, but the neurological damage can be permanent in some cases. Recovery can take days to weeks.

## Prevention: The Best Medicine

The most effective "treatment" for MDR1 drug sensitivity is prevention. This is a manageable condition, and affected dogs can live completely normal lives with a few simple precautions.

### Safe Parasite Prevention

Because ivermectin is common in heartworm preventives, owners of MDR1-affected Australian Shepherds must choose alternative products. Fortunately, there are several highly effective and safe options available.

- **Isoxazolines:** This class of drugs, which includes afoxolaner (NexGard), sarolaner (Simparica), and lotilaner (Credelio), is not affected by the MDR1 mutation. They are safe and effective for flea and tick prevention.
- **Milbemycin Oxime:** Found in products like Interceptor, this drug is often considered safer than ivermectin for MDR1-affected dogs. However, it should be used with caution and under veterinary supervision, as it is still a P-glycoprotein substrate.
- **Selamectin (Revolution):** This is a topical preventive that is generally considered safe for MDR1-affected dogs, but again, should be used under veterinary guidance.

**Always discuss all preventive options with your veterinarian.** They can help you choose the safest and most effective product based on your dog's specific needs, lifestyle, and the regional parasite risks. For example, the tick species and their prevalence vary significantly between North America and Europe, which may influence product choice.

### The Importance of Owner Communication

As an owner, you are the first line of defense. You must:

1.  **Know your dog's MDR1 status.**
2.  **Inform every veterinarian** you see, including emergency clinics, of your dog's status.
3.  **Read all medication labels** carefully.
4.  **Never administer over-the-counter medications** without explicit veterinary approval. This is especially true for loperamide (Imodium).

## The Broader Context of Australian Shepherd Health

While the MDR1 gene mutation is a critical health concern, it is not the only one for the breed. Being aware of other potential health problems is part of responsible pet ownership. For example, research has identified other genetic conditions in the breed. A 2023 study published in *Animal Genetics* identified a specific genetic variant (in the STK36 gene) associated with primary ciliary dyskinesia (PCD) in an Australian Shepherd [<a href="#ref-1">1</a>]. PCD is a condition characterized by impaired movement of cilia, leading to chronic respiratory infections and other organ system problems [<a href="#ref-1">1</a>]. This highlights that the breed is prone to a range of inherited conditions beyond drug sensitivities.

Another well-known breed-specific issue is the merle coat color pattern, which is caused by a SINE insertion in the PMEL gene [<a href="#ref-2">2</a>]. While beautiful, the merle gene requires careful breeding practices. When two merle dogs are bred together, there is a 25% chance of producing "double merle" puppies, which are often predominantly white and can suffer from severe deafness and blindness [<a href="#ref-2">2</a>]. Research has identified various forms of merle, including "cryptic" and "hidden" merle, which can be difficult to detect visually, making genetic testing crucial before breeding to avoid inadvertently producing double merle puppies [<a href="#ref-2">2</a>].

## Limitations and When to Contact a Veterinarian

This article provides a comprehensive overview of the MDR1 gene and ivermectin sensitivity in Australian Shepherds. However, it is crucial to understand its limitations. Breed-level information cannot predict the individual health status of your dog. The MDR1 mutation is just one of many genetic and environmental factors that influence your dog's overall health.

**The information here is educational and is not a substitute for veterinary diagnosis or treatment.**

You should contact your veterinarian in the following situations:

- **If you do not know your dog's MDR1 status**, schedule an appointment for a genetic test.
- **Before starting any new medication**, including parasite preventives, to confirm it is safe for your dog's MDR1 status.
- **If your dog shows any signs of illness**, such as lethargy, vomiting, diarrhea (or diarrhoea), incoordination, or seizures.
- **If you have any questions or concerns** about your dog's health or behavior (or behaviour).

Your veterinarian is your partner in your dog's healthcare. They can provide personalized advice and create a tailored health plan that addresses your dog's specific needs and risks. Do not hesitate to reach out to them with any concerns.

## The Genetic Basis of MDR1: A Deeper Look at P-Glycoprotein Function

To fully appreciate why the MDR1 mutation carries such profound clinical consequences, it helps to understand the normal physiology of P-glycoprotein in greater detail. P-glycoprotein is a member of the ATP-binding cassette (ABC) transporter family, a large group of membrane proteins that use energy from adenosine triphosphate (ATP) to move substrates across cellular membranes. This transporter is expressed in a tissue-specific pattern that reflects its protective role. Beyond the blood-brain barrier, the intestines, liver, and kidneys, P-glycoprotein is also found in the placenta, the testes, and the adrenal glands. In each of these locations, it serves as a gatekeeper, limiting the entry of xenobiotics, which are chemical substances foreign to the body, into sensitive tissues.

In the intestinal epithelium, P-glycoprotein sits on the apical surface of the cells, facing the gut lumen. When a drug like ivermectin is ingested, some of it is absorbed into the enterocytes, the cells lining the intestine. P-glycoprotein immediately pumps a portion of that absorbed drug back into the intestinal lumen, reducing the total amount that reaches the systemic circulation. This is known as first-pass elimination, and it is a major reason why oral ivermectin has a wide safety margin in genetically normal dogs. In an MDR1-affected dog, this intestinal pump is non-functional, meaning a larger fraction of an oral dose enters the bloodstream. The drug then travels to the brain, where the absence of functional P-glycoprotein at the blood-brain barrier allows it to accumulate unchecked.

The specific mutation responsible for this condition in Australian Shepherds is a four-base pair deletion in the MDR1 gene, often referred to as the ABCB1 gene in modern nomenclature. This deletion causes a frameshift mutation, which means that the genetic code is read incorrectly from that point forward. The result is a premature stop codon, leading to a truncated, non-functional protein. Because the mutation is a deletion, it is not something that can be "outgrown" or reversed. It is a permanent feature of the dog's genome, present in every cell of the body from the moment of conception.

The clinical implications of this defective pump extend beyond drug toxicity. P-glycoprotein also transports endogenous substances, including certain steroid hormones and peptides. While the full physiological consequences of MDR1 deficiency in dogs are not completely understood, researchers have noted that affected dogs may have altered responses to some endogenous compounds. However, the most clinically significant and well-documented effect remains the altered pharmacokinetics of P-glycoprotein substrate drugs.

## The Pharmacokinetics of Ivermectin in MDR1-Affected Dogs

Understanding how ivermectin behaves in the body, a field known as pharmacokinetics, clarifies why the MDR1 mutation turns a safe drug into a dangerous one. In a normal dog, ivermectin is absorbed after oral administration, distributes widely throughout the body, and is slowly metabolized by the liver. The drug is highly lipophilic, meaning it dissolves readily in fats, which allows it to penetrate tissues and accumulate in adipose tissue and the central nervous system. However, in a normal dog, the P-glycoprotein pump at the blood-brain barrier actively extrudes ivermectin from the brain parenchyma back into the bloodstream. This creates a concentration gradient where the drug levels in the brain remain low, typically less than one percent of the plasma concentration.

In an MDR1-affected dog, this protective efflux is absent. Ivermectin enters the brain and binds to glutamate-gated chloride channels, which are abundant in the central nervous system of mammals. These channels are normally involved in inhibitory neurotransmission. When ivermectin binds to them, it causes a sustained influx of chloride ions into neurons, hyperpolarizing the cells and making them less excitable. In a normal dog, the low brain concentration of ivermectin means this effect is minimal. In an affected dog, the high brain concentration leads to profound neuronal inhibition, manifesting as the clinical signs of depression, ataxia, coma, and respiratory depression.

The half-life of ivermectin in dogs is relatively long, ranging from one to two days. This means that once toxicity develops, the drug remains in the body for an extended period, and supportive care must be maintained for days, sometimes weeks, until the drug is slowly eliminated. The liver metabolizes ivermectin primarily through oxidative pathways, and the metabolites are excreted in bile and feces. In an affected dog, the lack of P-glycoprotein in the liver and bile ducts also impairs the biliary excretion of the drug, further prolonging its presence in the body and worsening the severity of toxicity.

## Breed Prevalence and the Importance of Population Screening

The prevalence of the MDR1 mutation in Australian Shepherds is strikingly high compared to many other breeds. Studies conducted in North America have reported that approximately 50 percent of Australian Shepherds carry at least one copy of the mutant allele. This means that roughly one in four Australian Shepherds is affected, possessing two copies of the mutation, and another one in four is a carrier. These numbers are sobering and underscore why this condition is considered a major breed-specific health problem.

The high prevalence is a consequence of the breed's population history. Australian Shepherds were developed from a relatively small founder population, and the breed experienced several population bottlenecks, periods when the number of breeding individuals was drastically reduced. These bottlenecks, combined with the popularity of certain influential sires, led to a founder effect, where a genetic variant present in a small number of ancestors became widespread in the descendant population. The MDR1 mutation likely existed in the foundational dogs of the breed and was propagated through generations of breeding, often unknowingly, because carriers and affected dogs appeared clinically normal until exposed to a triggering drug.

This population history has important implications for breeders. Even if a breeder has never observed a drug reaction in their dogs, they may still be producing affected puppies. The only way to know is through genetic testing. Responsible breeders now routinely test their breeding stock for the MDR1 mutation and make breeding decisions based on the results. The goal is to eliminate the mutation from the breed entirely, or at least reduce its frequency to negligible levels. This is achievable through a strategy known as "breeding away from the mutation," where affected dogs are removed from breeding programs, and carriers are only bred to genetically normal dogs, with the carrier offspring being identified and managed appropriately.

## Clinical Scenarios: When Toxicity Occurs

While the most common scenario for ivermectin toxicity is the administration of a heartworm preventive, there are other clinical situations where an MDR1-affected Australian Shepherd may be inadvertently exposed. One such scenario is the use of high-dose ivermectin to treat demodectic mange. Demodicosis, caused by the Demodex mite, is a common skin condition in dogs, and ivermectin is sometimes prescribed at doses that are 10 to 100 times higher than the heartworm preventive dose. In an MDR1-affected dog, even the low dose in a heartworm preventive can be dangerous, so the high doses used for mange are almost invariably fatal without immediate and aggressive intervention.

Another scenario involves the use of topical preparations. Some spot-on flea and tick products contain permethrin, a synthetic pyrethroid insecticide. While permethrin is not a P-glycoprotein substrate itself, it is highly toxic to cats and can cause severe reactions in dogs, particularly those with the MDR1 mutation. The mechanism is not entirely clear, but it is thought that the MDR1 mutation impairs the blood-brain barrier's ability to exclude permethrin, leading to tremors, seizures, and hyperthermia. Owners of MDR1-affected Australian Shepherds should be extremely cautious about using any permethrin-containing product, even those labeled for dogs, and should always consult their veterinarian first.

A third scenario involves accidental ingestion. An MDR1-affected dog may ingest a medication intended for another animal in the household, such as a monthly heartworm chewable for a larger dog or a different species. Because the dog's P-glycoprotein is non-functional, even a single dose of a drug that would be safe for a normal dog can precipitate toxicity. This is why it is critical to store all medications securely and out of reach of pets.

## Diagnostic Workflow: From Suspicion to Confirmation

When an Australian Shepherd presents with acute neurological signs, the diagnostic workflow must be rapid and systematic. The first step is a thorough history, with particular attention to any medications, preventives, or supplements administered in the preceding 24 to 72 hours. Owners should be asked to bring the packaging of any product they have given their dog, as this allows the veterinarian to identify the active ingredients and their concentrations.

The physical examination should include a complete neurological assessment, evaluating mentation, cranial nerve function, proprioception, and spinal reflexes. The presence of mydriasis, which is bilateral pupil dilation, is a common early finding in ivermectin toxicity. The dog may also exhibit a characteristic posture with a wide-based stance and a head tilt.

If the history and examination are consistent with drug toxicity, the veterinarian may recommend immediate genetic testing. While the results of a cheek swab test typically take several days to return from the laboratory, some veterinary diagnostic laboratories offer expedited testing with results available within 24 to 48 hours. In an emergency, the veterinarian may not wait for the genetic test results and will instead initiate treatment based on the clinical suspicion. However, a definitive genetic diagnosis is important for guiding long-term management and for confirming the cause of the episode.

There is no commercially available rapid test for ivermectin blood levels in most veterinary practices. Reference laboratories can measure ivermectin concentrations in serum, but the results are rarely available quickly enough to influence acute management. Therefore, the diagnosis of ivermectin toxicity is primarily clinical, supported by a history of exposure and, when available, a known MDR1 status.

## Differential Diagnoses: Ruling Out Other Causes of Neurological Signs

Not every Australian Shepherd that presents with neurological signs has ivermectin toxicity. The veterinarian must consider a range of differential diagnoses, which are other conditions that could produce similar clinical signs. These include:

- **Infectious diseases:** [Canine distemper virus](/knowledge/viruses/pet-viruses/canine-distemper-virus) can cause a range of neurological signs, including ataxia, tremors, and seizures. Tick-borne diseases such as ehrlichiosis and anaplasmosis can also cause neurological dysfunction.
- **Metabolic disorders:** Hepatic encephalopathy, caused by liver disease, can lead to depression, disorientation, and seizures. Hypoglycemia, or low blood sugar, can cause weakness, tremors, and collapse.
- **Toxins other than ivermectin:** Ethylene glycol (antifreeze) poisoning, chocolate toxicity, and metaldehyde (slug bait) toxicity can all cause neurological signs.
- **Trauma:** Head trauma from a fall or a motor vehicle accident can cause brain injury with signs ranging from mild disorientation to coma.
- **Idiopathic epilepsy:** Australian Shepherds can suffer from primary epilepsy, which typically presents as recurrent seizures without an identifiable underlying cause.

The diagnostic workup for these conditions may include blood work, including a complete blood count and serum biochemistry profile, to assess organ function and rule out metabolic causes. Urinalysis may be performed to check for evidence of ethylene glycol toxicity. Advanced imaging, such as magnetic resonance imaging (MRI) of the brain, may be recommended if a structural lesion is suspected. However, in a dog with a known history of drug exposure and a known MDR1 mutation, the diagnosis is often straightforward, and extensive testing may not be necessary.

## The Role of the Veterinary Emergency Clinic

If an MDR1-affected Australian Shepherd develops signs of toxicity, the owner should transport the dog to the nearest emergency veterinary clinic immediately. Time is of the essence, and delays in treatment can significantly worsen the prognosis. During transport, the owner should keep the dog calm and quiet, avoid giving any food or water, and be prepared to describe the drug that was administered, the dose, and the time of administration.

At the emergency clinic, the veterinary team will initiate stabilization measures. The first priority is to secure the airway, ensure adequate breathing, and maintain circulation, the so-called "ABCs" of emergency medicine. If the dog is comatose or has a depressed gag reflex, intubation may be necessary to protect the airway from aspiration. Intravenous access will be established, and fluids will be started to support blood pressure and promote diuresis.

If the drug was ingested within the last one to two hours and the dog is not showing severe neurological signs, the veterinarian may induce vomiting using a medication such as apomorphine. However, this is contraindicated in a dog that is already depressed or seizing, as there is a high risk of aspiration. Activated charcoal may be administered via a stomach tube to bind any remaining drug in the gastrointestinal tract. It is important to note that activated charcoal is most effective when given within a few hours of ingestion, before the drug has been fully absorbed.

## Advanced Treatment Modalities and Their Evidence Base

Beyond basic supportive care, several advanced treatment modalities have been described for the management of MDR1-related drug toxicity. One such modality is intravenous lipid emulsion (ILE) therapy. ILE is a fat emulsion that is administered intravenously and is thought to act as a "lipid sink," sequestering lipophilic drugs like ivermectin in the bloodstream and reducing their concentration in target tissues such as the brain. The evidence for ILE in veterinary toxicology is largely based on case reports and experimental studies, and its use is considered off-label. However, it is a relatively safe intervention with few adverse effects, and many veterinary emergency clinicians will consider it in severe cases of ivermectin toxicity.

Another treatment modality is the use of drugs that enhance the metabolism or excretion of ivermectin. Phenobarbital, a drug that induces hepatic enzymes, has been suggested as a potential adjunctive therapy, but its efficacy is unproven, and it carries its own risks of sedation and liver enzyme elevation. There is no specific antidote for ivermectin toxicity, and the cornerstone of treatment remains intensive supportive care.

The prognosis for an MDR1-affected dog with ivermectin toxicity is highly variable. Dogs that are treated early, before the onset of severe neurological signs, have a good chance of recovery. Dogs that present in a coma or with respiratory failure have a much more guarded prognosis, and the mortality rate in these cases is significant. Even in dogs that survive, there may be permanent neurological deficits, such as residual ataxia or behavioral changes. The recovery period can be prolonged, often requiring days to weeks of hospitalization and nursing care.

## Special Populations: Puppies, Senior Dogs, and Dogs with Comorbidities

The management of MDR1 drug sensitivity requires special consideration in certain populations. Puppies, for example, have a developing blood-brain barrier that may be more permeable to drugs than that of adult dogs. This means that even a puppy with a normal MDR1 status may be more sensitive to the effects of ivermectin than an adult dog. For an MDR1-affected puppy, the risks are even higher, and extreme caution is warranted. The first dose of a heartworm preventive is often given at around eight weeks of age, and this is a critical time to confirm the puppy's MDR1 status before administering any medication.

Senior dogs with the MDR1 mutation may have age-related changes in liver and kidney function that further impair drug metabolism and excretion. This can increase the risk of toxicity even with drugs that are normally considered safe. Additionally, senior dogs are more likely to be on multiple medications for chronic conditions such as arthritis, heart disease, or hypothyroidism. The potential for drug interactions must be carefully considered, as some medications can inhibit P-glycoprotein function even in dogs with a normal MDR1 gene, effectively phenocopying the mutation.

Dogs with pre-existing neurological conditions, such as epilepsy or vestibular disease, may be more susceptible to the neurological effects of P-glycoprotein substrate drugs. In these dogs, even a mild drug reaction could exacerbate their underlying condition, leading to a more severe clinical presentation. Owners of these dogs should work closely with their veterinarian to develop a preventive plan that minimizes the use of any potentially problematic drugs.

## The Intersection of MDR1 and Other Australian Shepherd Health Concerns

The MDR1 mutation does not exist in a vacuum. Australian Shepherds are predisposed to a range of other health conditions, and the management of these conditions must be integrated with MDR1 status. For example, Australian Shepherds are prone to hip dysplasia, a developmental condition of the hip joint that can lead to arthritis and pain. The treatment for arthritis often involves non-steroidal anti-inflammatory drugs (NSAIDs), which are not P-glycoprotein substrates and are generally safe in MDR1-affected dogs. However, if the dog also requires a medication for a concurrent condition that is a P-glycoprotein substrate, the veterinarian must carefully weigh the risks and benefits.

Another common condition in the breed is progressive retinal atrophy (PRA), a group of genetic diseases that cause degeneration of the retina and eventual blindness. There is no treatment for PRA, and the management is supportive. However, the diagnosis of PRA may involve electroretinography, a test that requires sedation. The choice of sedative must take into account the dog's MDR1 status, as some sedatives are P-glycoprotein substrates.

The merle coat color gene, as mentioned in the main article, is another important genetic consideration in Australian Shepherds. The merle gene is associated with a range of auditory and ophthalmic abnormalities, particularly in double merle dogs. Research has shown that the length of the SINE insertion in the PMEL gene correlates with the severity of the merle phenotype and the associated health risks [<a href="#ref-2">2</a>]. Dogs with a longer insertion tend to have a more pronounced merle pattern and a higher risk of deafness and microphthalmia, a condition where the eyes are abnormally small. Breeders who are working to eliminate the MDR1 mutation from their lines must also be mindful of the merle gene, as the two genetic traits are inherited independently.

## Owner Observation: Recognizing the Early Signs of a Reaction

Owners of MDR1-affected Australian Shepherds must be vigilant observers. The early signs of a drug reaction can be subtle and may be mistaken for other conditions. For example, a dog that becomes lethargic and refuses to eat a few hours after receiving a heartworm preventive may be experiencing the early effects of ivermectin toxicity. Similarly, a dog that seems unsteady on its feet or is drooling excessively may be showing the first signs of neurological involvement.

Owners should be particularly alert in the 24 to 48 hours following the administration of any new medication. This is the window in which most adverse reactions will manifest. If any of the following signs are observed, the owner should contact their veterinarian immediately:

- Lethargy or depression that is out of proportion to the dog's normal behavior
- Loss of appetite or vomiting
- Excessive drooling or foaming at the mouth
- Unsteady gait, stumbling, or falling
- Tremors or muscle twitching
- Dilated pupils or apparent blindness
- Disorientation or confusion
- Difficulty breathing or changes in respiratory rate

It is important to note that not all reactions occur immediately. In some cases, signs may not appear until 24 to 48 hours after drug administration. This is because the drug may take time to accumulate to toxic levels in the brain. Owners should not assume that a dog is safe simply because it appeared normal for the first few hours after receiving a medication.

## Preparing for a Veterinary Visit: What to Bring and What to Ask

When an owner schedules a veterinary visit to discuss MDR1 testing or to address a potential drug reaction, preparation can make the visit more productive. The owner should bring the following items:

- A list of all medications, supplements, and preventives the dog has received in the past month, including the dates of administration and the doses
- The packaging or labels from any recent medications, so the veterinarian can verify the active ingredients
- Any previous medical records, including results of prior genetic testing
- A written list of questions or concerns

During the visit, the owner should be prepared to discuss the dog's history in detail. The veterinarian will want to know about the dog's age, breed, and lifestyle, as well as any previous adverse reactions to medications. If the dog has not yet been tested for the MDR1 mutation, the veterinarian will likely recommend testing. The owner should ask about the cost of the test, the turnaround time for results, and what the results will mean for the dog's future care.

If the visit is for a suspected drug reaction, the owner should be prepared to describe the onset and progression of signs. The veterinarian will want to know exactly when the drug was administered, the dose, and the route of administration. The owner should also be prepared to describe the dog's neurological status, including whether the dog is responsive, able to stand, and able to eat and drink.

## The Long-Term Management Plan for an MDR1-Affected Dog

Once an Australian Shepherd has been diagnosed as affected with the MDR1 mutation, a long-term management plan should be established. This plan should be documented in writing and shared with all members of the household, as well as with any future veterinarians or pet sitters. The plan should include the following components:

- A list of drugs that are strictly contraindicated, including ivermectin, loperamide, and certain chemotherapeutic agents
- A list of drugs that can be used with caution, including milbemycin oxime and selamectin
- A list of drugs that are generally safe, including the isoxazoline class of flea and tick preventives
- Instructions for what to do in the event of an accidental exposure, including the phone number of the nearest emergency veterinary clinic
- A schedule for regular veterinary check-ups, with a reminder to review the MDR1 status at each visit

The owner should also consider obtaining a medical alert tag or bracelet for the dog. This is a small tag that attaches to the dog's collar and alerts anyone who finds the dog to its MDR1 status. In an emergency, this tag could be life-saving, as it would alert veterinary personnel to the dog's condition even if the owner is not present.

## The Role of Genetic Counseling in Breeding Decisions

For breeders of Australian Shepherds, the MDR1 mutation presents both a challenge and an opportunity. The challenge is to reduce the frequency of the mutation in the breed while maintaining genetic diversity. The opportunity is to use modern genetic tools to make informed breeding decisions that improve the overall health of the breed.

Genetic counseling for breeders involves several steps. First, all breeding stock should be tested for the MDR1 mutation. The results should be recorded and used to guide breeding pairings. The goal is to avoid producing affected puppies, which requires that at least one parent be genetically normal (N/N). If a carrier (M/M) is bred to a normal dog, the resulting litter will be approximately 50 percent normal and 50 percent carriers, with no affected puppies. If two carriers are bred, there is a 25 percent chance of producing an affected puppy, a 50 percent chance of producing a carrier, and a 25 percent chance of producing a normal puppy.

Breeders should also consider the broader genetic health of their lines. The MDR1 mutation is just one of several genetic conditions that can affect Australian Shepherds. Other conditions include hereditary cataracts, iris coloboma, and canine multifocal retinopathy. A comprehensive genetic testing panel can assess the dog's status for multiple conditions simultaneously, allowing the breeder to make more informed decisions.

It is important to note that eliminating the MDR1 mutation entirely from the breed is a long-term goal that may take many generations. In the meantime, the focus should be on reducing the frequency of the mutation while maintaining the breed's characteristic temperament, working ability, and conformation. This requires a balanced approach that considers both genetic health and breed type.

## The Evidence Base: What We Know and What We Do Not Know

The understanding of the MDR1 mutation in Australian Shepherds is built on a substantial body of research, but there are still gaps in the evidence base. What is well established is the causal relationship between the four-base pair deletion in the MDR1 gene and the altered pharmacokinetics of P-glycoprotein substrate drugs. This has been confirmed through molecular genetic studies, in vitro experiments using cell lines expressing the mutant protein, and clinical observations of affected dogs.

What is less well understood is the full spectrum of drugs that can cause adverse reactions in MDR1-affected dogs. The list of known P-glycoprotein substrates is constantly evolving, and new drugs are being developed that may interact with the transporter. This is why it is essential for owners to consult their veterinarian before administering any new medication, even if it is not on the current list of contraindicated drugs.

Another area of uncertainty is the degree of drug sensitivity in carrier dogs. While carriers have one functional copy of the MDR1 gene, the expression of P-glycoprotein may be reduced compared to normal dogs. Some studies have suggested that carriers may be more sensitive to high doses of ivermectin, but the clinical significance of this finding is debated. In general, carriers are considered to be at lower risk than affected dogs, but they should still avoid high-dose ivermectin and use caution with other P-glycoprotein substrates.

The long-term prognosis for MDR1-affected dogs that survive a toxic episode is also not well characterized. While many dogs recover fully, some may have residual neurological deficits. The factors that predict a good versus a poor outcome are not fully understood, but the dose of the drug, the speed of treatment initiation, and the severity of the initial clinical signs are likely important.

## The Global Perspective: MDR1 in Australian Shepherds Worldwide

The prevalence of the MDR1 mutation in Australian Shepherds varies by geographic region. Studies from North America have reported the highest prevalence, with approximately 50 percent of dogs carrying at least one mutant allele. Studies from Europe have reported a somewhat lower prevalence, but the mutation is still present at significant levels. This geographic variation is likely due to differences in breed history and breeding practices between regions.

For owners and breeders outside North America, it is important to recognize that the MDR1 mutation is a global concern. Even if a dog was imported from a region with a lower prevalence, it could still be affected or a carrier. Genetic testing is the only way to know for certain, and it should be performed on all Australian Shepherds, regardless of their country of origin.

The global nature of the breed also means that veterinarians around the world need to be aware of the MDR1 mutation and its implications. A veterinarian in Europe or Asia may be less familiar with the condition than a veterinarian in North America, where it is more commonly discussed. Owners should be prepared to educate their veterinarian about the condition and to advocate for their dog's safety.

## Integrating MDR1 Awareness into Routine Preventive Care

The MDR1 mutation should be a routine consideration in the preventive care of every Australian Shepherd. This means that at the puppy's first veterinary visit, the veterinarian should discuss the MDR1 mutation and recommend genetic testing. The results of the test should be recorded in the dog's medical record and flagged so that any future veterinarian who sees the dog is aware of the status.

At each subsequent wellness visit, the veterinarian should review the dog's medication list and confirm that all prescribed drugs are safe for the dog's MDR1 status. This is particularly important when the dog reaches middle age, as the risk of chronic conditions requiring medication increases.

Owners should also be educated about the signs of a drug reaction and the importance of seeking immediate veterinary care if a reaction is suspected. This education should be reinforced at every visit, as owners may forget the details over time.

## The Psychological Impact on Owners

The diagnosis of an MDR1 mutation in an Australian Shepherd can be distressing for owners. Many owners feel a sense of guilt, wondering if they could have done something to prevent the condition. It is important to reassure owners that the MDR1 mutation is a genetic condition that is not their fault. It is inherited from the dog's parents and cannot be prevented through diet, exercise, or any other aspect of care.

Owners may also feel anxious about the future, worrying about the risk of accidental drug exposure and the potential consequences. This anxiety is understandable, but it can be managed through education and preparation. By knowing their dog's MDR1 status, working closely with their veterinarian, and having a clear plan in place, owners can significantly reduce the risk of a toxic episode.

Support groups and online communities for owners of MDR1-affected dogs can be a valuable resource. These groups provide a forum for owners to share their experiences, ask questions, and offer support to one another. They can also be

## Frequently Asked Questions

### 1. What is the MDR1 gene mutation in Australian Shepherds?
The MDR1 gene mutation is a genetic defect that results in the production of a faulty P-glycoprotein, a protein responsible for pumping certain drugs and toxins out of the brain. This makes affected Australian Shepherds dangerously sensitive to drugs like ivermectin.

### 2. How do I know if my Australian Shepherd has the MDR1 gene mutation?
The only way to know for sure is through a genetic test. A veterinarian can perform a simple cheek swab or blood test, which is then sent to a laboratory for analysis.

### 3. Is ivermectin safe for Australian Shepherds?
Ivermectin is not safe for Australian Shepherds with the MDR1 gene mutation. Even standard doses found in heartworm preventives can cause severe, life-threatening neurological toxicity in affected dogs.

### 4. What are the signs of ivermectin toxicity in a dog?
Signs of ivermectin toxicity include lethargy, vomiting, dilated pupils, lack of coordination, tremors, disorientation, blindness, seizures, coma, and respiratory failure. These signs require immediate emergency veterinary care.

### 5. What parasite prevention is safe for an MDR1-affected Australian Shepherd?
Isoxazoline drugs like afoxolaner (NexGard) and sarolaner (Simparica) are generally considered safe for MDR1-affected dogs. Other options like milbemycin oxime (Interceptor) and selamectin (Revolution) can be used with caution and under veterinary supervision.

### 6. Can I give my Australian Shepherd Imodium (loperamide) for diarrhea?
No. Loperamide is contraindicated in dogs with the MDR1 mutation. It can cause severe sedation and neurological signs. Always consult your veterinarian before giving any over-the-counter medication to your dog.

### 7. If my dog is a carrier of the MDR1 mutation, is it a problem?
A carrier (having one copy of the mutation) may have some increased drug sensitivity compared to a normal dog, but the risk is significantly lower than for an affected dog (with two copies). However, carriers can pass the mutation to their offspring, so breeding decisions should be made carefully.

### 8. Can an Australian Shepherd with the MDR1 mutation live a normal life?
Yes, absolutely. With a definitive diagnosis and careful management, including avoiding all contraindicated drugs, an MDR1-affected Australian Shepherd can live a long, healthy, and completely normal life.

<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "FAQPage",
  "mainEntity": [
    {
      "@type": "Question",
      "name": "What is the MDR1 gene mutation in Australian Shepherds?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The MDR1 gene mutation is a genetic defect that results in the production of a faulty P-glycoprotein, a protein responsible for pumping certain drugs and toxins out of the brain. This makes affected Australian Shepherds dangerously sensitive to drugs like ivermectin."
      }
    },
    {
      "@type": "Question",
      "name": "How do I know if my Australian Shepherd has the MDR1 gene mutation?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The only way to know for sure is through a genetic test. A veterinarian can perform a simple cheek swab or blood test, which is then sent to a laboratory for analysis."
      }
    },
    {
      "@type": "Question",
      "name": "Is ivermectin safe for Australian Shepherds?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Ivermectin is not safe for Australian Shepherds with the MDR1 gene mutation. Even standard doses found in heartworm preventives can cause severe, life-threatening neurological toxicity in affected dogs."
      }
    },
    {
      "@type": "Question",
      "name": "What are the signs of ivermectin toxicity in a dog?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Signs of ivermectin toxicity include lethargy, vomiting, dilated pupils, lack of coordination, tremors, disorientation, blindness, seizures, coma, and respiratory failure. These signs require immediate emergency veterinary care."
      }
    },
    {
      "@type": "Question",
      "name": "What parasite prevention is safe for an MDR1-affected Australian Shepherd?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Isoxazoline drugs like afoxolaner (NexGard) and sarolaner (Simparica) are generally considered safe for MDR1-affected dogs. Other options like milbemycin oxime (Interceptor) and selamectin (Revolution) can be used with caution and under veterinary supervision."
      }
    },
    {
      "@type": "Question",
      "name": "Can I give my Australian Shepherd Imodium (loperamide) for diarrhea?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "No. Loperamide is contraindicated in dogs with the MDR1 mutation. It can cause severe sedation and neurological signs. Always consult your veterinarian before giving any over-the-counter medication to your dog."
      }
    },
    {
      "@type": "Question",
      "name": "If my dog is a carrier of the MDR1 mutation, is it a problem?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "A carrier (having one copy of the mutation) may have some increased drug sensitivity compared to a normal dog, but the risk is significantly lower than for an affected dog (with two copies). However, carriers can pass the mutation to their offspring, so breeding decisions should be made carefully."
      }
    },
    {
      "@type": "Question",
      "name": "Can an Australian Shepherd with the MDR1 mutation live a normal life?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Yes, absolutely. With a definitive diagnosis and careful management, including avoiding all contraindicated drugs, an MDR1-affected Australian Shepherd can live a long, healthy, and completely normal life."
      }
    }
  ]
}
</script>

## Sources

<a id="ref-1"></a>[<a href="#ref-1">1</a>] [STK36 splice site variant in an Australian Shepherd dog with primary ciliary dyskinesia.](https://pubmed.ncbi.nlm.nih.gov/36786090/)

<a id="ref-2"></a>[<a href="#ref-2">2</a>] [The PMEL gene and merle (dapple) in the dachshund: cryptic, hidden, and mosaic variants demonstrate the need for genetic testing prior to breeding.](https://pubmed.ncbi.nlm.nih.gov/34370083/)

<a id="ref-3"></a>[<a href="#ref-3">3</a>] [Exploring presentation differences in multi-cultural youth seeking assistance for mental health problems.](https://pubmed.ncbi.nlm.nih.gov/33906682/)

<a id="ref-4"></a>[<a href="#ref-4">4</a>] [Relationships between Psychosocial Resilience and Physical Health Status of Western Australian Urban Aboriginal Youth.](https://pubmed.ncbi.nlm.nih.gov/26716829/)

<a id="ref-5"></a>[<a href="#ref-5">5</a>] [Psychosocial disadvantage and residential remoteness is associated with Aboriginal women's mental health prior to childbirth.](https://pubmed.ncbi.nlm.nih.gov/32935056/)

<a id="ref-6"></a>[<a href="#ref-6">6</a>] [Trends in mental health related contacts among mothers of Aboriginal children in Western Australia (1990-2013): a linked data population-based cohort study of over 40 000 children.](https://pubmed.ncbi.nlm.nih.gov/31266837/)

<a id="ref-7"></a>[<a href="#ref-7">7</a>] [A Scalability Assessment of an Organizational Health Literacy Initiative to Support Health Professionals in Developing Quality Consumer Information.](https://pubmed.ncbi.nlm.nih.gov/42338081/)

<a id="ref-8"></a>[<a href="#ref-8">8</a>] [Study protocol of EMPOWER: A cluster randomized trial of a multimodal eHealth intervention for promoting mental health in the workplace following a stepped wedge trial design.](https://pubmed.ncbi.nlm.nih.gov/36276189/)

<a id="ref-9"></a>[<a href="#ref-9">9</a>] [Prevalence and predictors of vitamin D deficiency in a nationally representative sample of Australian Aboriginal and Torres Strait Islander adults.](https://pubmed.ncbi.nlm.nih.gov/33028435/)

<a id="ref-10"></a>[<a href="#ref-10">10</a>] [Socioeconomic disparities in the mental health of Indigenous children in Western Australia.](https://pubmed.ncbi.nlm.nih.gov/22958495/)

<a id="ref-11"></a>[<a href="#ref-11">11</a>] [Policy and service development implications of the second Australian National Survey of High Impact Psychosis (SHIP).](https://pubmed.ncbi.nlm.nih.gov/22563037/)

<a id="ref-12"></a>[<a href="#ref-12">12</a>] [Socioeconomic disparities in physical health among Aboriginal and Torres Strait Islander children in Western Australia.](https://pubmed.ncbi.nlm.nih.gov/22292856/)

<div data-calculator="toxicity"></div>

## Related Clinical & Scientific Guides

* [Birman Health Problems: Inherited Conditions and Cardiac Screenings](/knowledge/veterinary-medicine/breed-specific-health/birman-health-problems-inherited-conditions-and-cardiac-screenings)
* [Singapura Cat Health Problems: Inherited Conditions and Cardiac Screenings](/knowledge/veterinary-medicine/breed-specific-health/singapura-cat-health-problems-inherited-conditions-and-cardiac-screenings)
* [Siberian Cat Health Problems: Inherited Conditions and Cardiac Screenings](/knowledge/veterinary-medicine/breed-specific-health/siberian-cat-health-problems-inherited-conditions-and-cardiac-screenings)